Please ensure Javascript is enabled for purposes of website accessibility

Why GW Pharmaceuticals Stock Plunged in February

By George Budwell - Mar 6, 2020 at 9:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GW Pharmaceuticals' stock took a beating last month. Here's why.

What happened

Shares of British drugmaker GW Pharmaceuticals (GWPH) shed an eye-catching 11.4% of their value in February, according to data from S&P Global Market Intelligence. The company took a big hit after reporting fourth-quarter and full-year results on Feb. 25, but earnings weren't the whole story behind this hefty downturn. 

Specifically, GW Pharmaceuticals' stock was hammered for two interrelated reasons last month. First, the company posted a larger net loss for the fourth quarter than the prevailing consensus estimate. Second, this earnings miss couldn't have come at a worse time. The entire market was in free fall at the end of February thanks to the COVID-19 illness, and pharma stocks like GW Pharmaceuticals were some of the hardest hit by this wave of panic selling. 

A professional-looking woman staring at a laptop with a look of shock on her face.

Image source: Getty Images.

So what

GW Pharmaceuticals' stock is now trading close to its three-year low following last month's downturn. Moreover, the drugmaker's shares are currently valued at just 3.9 times next year's projected sales. That's not super cheap to be sure, but it's also not a particularly pricey valuation for a rare disease play. Most of these orphan-drug companies, after all, trade at over 10 times forward-looking sales, so there's a strong case to be made here that GW is now in bargain territory.

Now what

Is it time to buy? GW Pharmaceuticals' cannabis-based epilepsy medicine Epidiolex has gotten off to a roaring start since its launch. What's more, the company is making progress on several other pipeline candidates as well. Therefore, bargain hunters may want to consider buying this beaten-down pharma stock in the wake of this February swoon. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.